XML 38 R21.htm IDEA: XBRL DOCUMENT
v3.23.1

SEGMENT REPORTING | 12 Months Ended
--- | ---
Sep. 30, 2022
SEGMENT REPORTING |
SEGMENT REPORTING | NOTE 15 – SEGMENT REPORTING ASC 280, “Segment Reporting”, establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organizational structure as well as information about geographical areas, business segments and major customers in financial statements for details on the Company’s business segments. The Company uses the “management approach” in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company’s chief operating decision maker for making operating decisions and assessing performance as the source for determining the Company’s reportable segments. Management, including the chief operating decision maker, reviews operation results by the revenue of different products. Based on management’s assessment, the Company has determined that it has three operating segments as defined by ASC 280. The Company, its subsidiaries, the VIE and VIE’s subsidiaries mainly manufactures and distributes active pharmaceutical ingredients and TCMD products as well as other by-products in China. Currently no revenue is derived from international markets. The following table presents segment information for years ended September 30, 2022, 2021 and 2020, respectively: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended September 30, 2022
​ | ​ | Oxytetracycline | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | & Licorice | ​ | ​ | ​ | ​ | Heparin | ​ | ​ | ​
​ | ​ | products and | ​ | ​ | ​ | ​ | products and | ​ | ​ | ​
​ | ​ | TCMD | ​ | Fertilizer | ​ | Sausage casing | ​ | Total
Revenue |  | $ | 40,305,988 |  | $ | 1,088,570 |  | $ | 23,460,467 |  | $ | 64,855,025
Cost of revenue | ​ |  | 36,210,950 | ​ |  | 760,030 | ​ |  | 21,656,748 | ​ |  | 58,627,728
Gross profit | ​ | $ | 4,095,038 | ​ | $ | 328,540 | ​ | $ | 1,803,719 | ​ | $ | 6,227,297
Depreciation and amortization | ​ | $ | 963,457 | ​ | $ | 48,804 | ​ | $ | 212,412 | ​ | $ | 1,224,673
Capital expenditures | ​ | $ | 1,882,198 | ​ | $ | 91,029 | ​ | $ | 1,259,042 | ​ | $ | 3,232,269
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended September 30, 2021
​ | ​ | Oxytetracycline | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | & Licorice | ​ | ​ | ​ | ​ | Heparin | ​ | ​ | ​
​ | ​ | products and | ​ | ​ | ​ | ​ | products and | ​ | ​ | ​
​ | ​ | TCMD | ​ | Fertilizer | ​ | Sausage casing | ​ | Total
Revenue |  | $ | 33,451,159 |  | $ | 486,171 |  | $ | 23,162,554 |  | $ | 57,099,884
Cost of revenue | ​ |  | 28,362,016 | ​ |  | 463,738 | ​ |  | 22,635,600 | ​ |  | 51,461,354
Gross profit | ​ | $ | 5,089,143 | ​ | $ | 22,433 | ​ | $ | 526,954 | ​ | $ | 5,638,530
Depreciation and amortization | ​ | $ | 951,015 | ​ | $ | 47,194 | ​ | $ | 203,020 | ​ | $ | 1,201,229
Capital expenditures | ​ | $ | 3,321,629 | ​ | $ | 46,169 | ​ | $ | 125,576 | ​ | $ | 3,493,374
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended September 30, 2020
​ | ​ | Oxytetracycline | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | & Licorice | ​ | ​ | ​ | ​ | Heparin | ​ | ​ | ​
​ | ​ | products and | ​ | ​ | ​ | ​ | products and | ​ | ​ | ​
​ | ​ | TCMD | ​ | Fertilizer | ​ | Sausage casing | ​ | Total
Revenue |  | $ | 32,602,384 |  | $ | 701,701 |  | $ | 16,729,115 |  | $ | 50,033,200
Cost of revenue | ​ |  | 25,004,712 | ​ |  | 304,670 | ​ |  | 17,184,665 | ​ |  | 42,494,047
Gross profit | ​ | $ | 7,597,672 | ​ | $ | 397,031 | ​ | $ | (455,550) | ​ | $ | 7,539,153
Depreciation and amortization | ​ | $ | 886,323 | ​ | $ | 38,792 | ​ | $ | 180,473 | ​ | $ | 1,105,588
Capital expenditures | ​ | $ | 377,953 | ​ | $ | 33,914 | ​ | $ | 37,898 | ​ | $ | 449,765
​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | September 30,
​ | ​ | 2022 | ​ | 2021
Total Assets |  | ​ |  |  | ​ |
Oxytetracycline & Licorice products and TCMD | ​ | $ | 50,690,503 | ​ | $ | 60,786,870
Fertilizer | ​ | $ | 2,613,859 | ​ | $ | 2,540,189
Heparin products and Sausage casing | ​ | $ | 11,222,255 | ​ | $ | 12,026,204
Total | ​ | $ | 64,526,617 | ​ | $ | 75,353,263
​

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration